{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:09:06Z","timestamp":1788901746988,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T00:00:00Z","timestamp":1285113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Lower alimentary tract mucositis is a serious complication of chemotherapy. The aim of the study was to determine the incidence, risk factors, and mortality of lower alimentary tract mucositis in a homogeneous population of patients with newly diagnosed myeloma receiving similar antineoplastic therapy and standardized supportive care.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Lower alimentary tract mucositis was evaluated among 303 consecutive patients with myeloma (2004\u20102007) enrolled in a clinical trial consisting of induction chemotherapy, tandem melphalan\u2010based autologous stem cell transplantation (ASCT), and consolidation. Lower alimentary tract mucositis was defined as neutropenia\u2010associated grade II\u2010IV enteritis\/colitis. Pretreatment risk factors were examined including body surface area (BSA), serum albumin (albumin), and estimated creatinine clearance (CrCl). Multiple logistic regression model was used to compute adjusted odds ratio (OR) and 95% confidence intervals (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Forty\u2010seven (15.5%) patients developed lower alimentary tract mucositis during 1529 courses of chemotherapy (including 536 melphalan\u2010based ASCT). Pre\u2010enrollment BSA &lt;2 m<jats:sup>2<\/jats:sup> (OR, 2.768; 95% CI, 1.200\u20106.381; <jats:italic>P<\/jats:italic> = .0169) increased the risk for lower alimentary tract mucositis, whereas higher albumin was protective (OR, 0.698; 95% CI, 0.519\u20100.940; <jats:italic>P<\/jats:italic> = .0177). Pretransplant variables associated with lower alimentary tract mucositis were BSA &lt;2 m<jats:sup>2<\/jats:sup> (OR, 4.451; 95% CI, 1.459\u201013.58, <jats:italic>P<\/jats:italic> = .0087) and estimated CrCl &lt;60 mL\/min (OR, 3.493; 95% CI, 1.173\u201010.40; <jats:italic>P<\/jats:italic> = .0246). Higher albumin level conferred protection (OR, 0.500; 95% CI, 0.304\u20100.820; <jats:italic>P<\/jats:italic> = .0061). No lower alimentary tract mucositis\u2010related death was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Lower alimentary tract mucositis is not uncommon among a homogenous population of oncology patients undergoing sequential courses of chemotherapy including melphalan\u2010based ASCT but does not contribute to mortality. Lower BSA, renal function, and albumin are associated with increased risk for lower alimentary tract mucositis. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25633","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T10:34:54Z","timestamp":1285151694000},"page":"648-655","source":"Crossref","is-referenced-by-count":30,"title":["Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients"],"prefix":"10.1002","volume":"117","author":[{"given":"Somashekar G.","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica L.","family":"Grazziutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sanathkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Anaissie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003437"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2254"},{"key":"e_1_2_6_4_2","first-page":"44","article-title":"Neutropenic enterocolitis","volume":"22","author":"Davila ML.","year":"2006","journal-title":"Curr Opin Gastroenterol."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2008.061"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00442.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06639.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705471"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.01.003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0b013e328324e6ad"},{"key":"e_1_2_6_11_2","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published August 9 2006. Available at:http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed on September 2 2007."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040125"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700765"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702447"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705797"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100336"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e3281108025"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07342.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.66"},{"key":"e_1_2_6_21_2","volume-title":"Alkeran\u00ae (Melphalan Hydrochloride) for Injection Prescribing Information","author":"Wellcome G.","year":"1998"},{"key":"e_1_2_6_22_2","first-page":"2379","article-title":"Pharmacokinetics of high\u2010dose melphalan in adults: influence of renal function","volume":"14","author":"Kergueris MF","year":"1994","journal-title":"Anticancer Res."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03033.x"},{"key":"e_1_2_6_24_2","first-page":"684","article-title":"Intermediate\u2010dose (25mg\/m2) IV melphalan for multiple myeloma with renal failure","volume":"15","author":"Vigneau C","year":"2002","journal-title":"J Nephrol."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.25.695"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2002.172"},{"key":"e_1_2_6_27_2","unstructured":"1985 Bristol Laboratories Evansville IN"},{"key":"e_1_2_6_28_2","unstructured":"2002 Bedford Laboratories Bedford OH"},{"key":"e_1_2_6_29_2","unstructured":"Prescribing Information. Cambridge MA: Millennium Pharmaceuticals Inc Rev 9. June2008."},{"key":"e_1_2_6_30_2","unstructured":"2003 SicorPharmaceuticals Irvine CA"},{"key":"e_1_2_6_31_2","unstructured":"1990 Bristol\u2010Myers Oncology Division Evansville IN"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21134"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.756"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i9.1397"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2263011932"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2008.10.094"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2008.10.029"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep1277"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920101)69:1<17::AID-CNCR2820690106>3.0.CO;2-X"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03434.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100106141"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-5710(97)00586-0"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-006-0092-y"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr0804223"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/514946"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198710000-00008"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.3.484"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4784"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25633","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:15:09Z","timestamp":1760274909000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25633"}},"subtitle":["Clinical and research implications"],"short-title":[],"issued":{"date-parts":[[2010,9,22]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1002\/cncr.25633"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25633","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,22]]}}}